You might also like
STERIS is a leading global provider of products and services focused on infection prevention, supporting patient care through innovative healthcare and life science solutions. The company operates in three main business segments: Healthcare, Applied Sterilization Technologies (AST), and Life Sciences . STERIS offers a comprehensive range of products and services, including infection prevention consumables, capital equipment like sterilizers and surgical tables, and services such as equipment maintenance and instrument repair . The company has divested its Dental segment to focus on core markets in healthcare, pharma, and MedTech .
- Healthcare - Offers a comprehensive range of products and services for healthcare providers, including infection prevention consumables, capital equipment like sterilizers and surgical tables, and services such as equipment maintenance and instrument repair .
- Applied Sterilization Technologies (AST) - Provides contract sterilization and laboratory testing services for medical device and pharmaceutical manufacturers, offering a technology-neutral approach from testing through sterilization .
- Life Sciences - Supports biopharmaceutical and medical device research and manufacturing facilities with products like pharmaceutical detergents, sterilizers, and maintenance services .
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
Andrew Xilas Executive | Senior Vice President and General Manager, Dental | None | Andrew Xilas transitioned into STERIS leadership following the acquisition of HuFriedyGroup. | |
Cary L. Majors Executive | Senior Vice President and President, Healthcare | None | Cary L. Majors has been with STERIS since 2014, serving in various leadership roles within the company. | |
Daniel A. Carestio Executive | President and CEO | None | Daniel A. Carestio has extensive experience in all operating aspects of STERIS's business and is familiar with healthcare and related industries. He leads the management team and assists the Board in its oversight of the company. | View Report → |
J. Adam Zangerle Executive | Senior Vice President, General Counsel, and Secretary | None | J. Adam Zangerle oversees legal, compliance, and corporate governance matters for STERIS. | |
Julia K. Madsen Executive | Senior Vice President and General Manager, Life Sciences | None | Julia K. Madsen has been with STERIS since 2015, progressing to her current leadership role in the Life Sciences division. | |
Karen L. Burton Executive | Vice President and Chief Accounting Officer | None | Karen L. Burton has been with STERIS since 2017, serving as Chief Accounting Officer and previously as Controller. | |
Kenneth E. Kohler Executive | Senior Vice President and General Manager, AST | None | Kenneth E. Kohler has been with STERIS since 2015, overseeing operations in the Applied Sterilization Technologies division. | |
Mary Clare Fraser Executive | Senior Vice President and Chief Human Resources Officer | None | Mary Clare Fraser joined STERIS in 2020 and was promoted to her current role in 2022. She has a background in human resources leadership. | |
Michael J. Tokich Executive | Senior Vice President and Chief Financial Officer | None | Michael J. Tokich has been with STERIS since 2017, serving as CFO. He has held various financial leadership roles within the company. | |
Renato G. Tamaro Executive | Vice President and Corporate Treasurer | None | Renato G. Tamaro has been with STERIS since 2006, serving as Corporate Treasurer since 2017. | |
Christopher S. Holland Board | Director | Director at Jabil Inc. | Christopher S. Holland has been a director at STERIS since 2020, with extensive financial experience in the healthcare industry. | |
Cynthia L. Feldmann Board | Director | Director at UFP Technologies, Inc. and Alexandria Real Estate Equities, Inc. | Cynthia L. Feldmann has been a director at STERIS since 2005, bringing extensive experience in financial oversight and governance. | |
Esther M. Alegria Board | Director | Founder and Chief Innovation Officer of APIE Therapeutics; Board Member at Avid Bioservices, Inc. | Esther M. Alegria brings over three decades of experience in the biopharmaceutical industry to STERIS's Board. | |
Jacqueline B. Kosecoff Board | Director | Director at Houlihan Lokey, Alignment Healthcare, and TriNet Group, Inc. | Jacqueline B. Kosecoff has been a director at STERIS since 2003, with extensive experience in the healthcare industry. | |
Mohsen M. Sohi Board | Chairman of the Board | CEO of Freudenberg SE; Board Member at Baker Hughes and Tetra Laval | Mohsen M. Sohi has been a director at STERIS since 2005 and serves as Chairman of the Board. He is also the CEO of Freudenberg SE and holds board positions at Baker Hughes and Tetra Laval. | |
Nirav R. Shah Board | Director | Faculty at Stanford University; Chief Medical Officer of American Health Associates | Nirav R. Shah has been a director at STERIS since 2018, with extensive experience in public health policy and healthcare management. | |
Paul E. Martin Board | Director | Director at Unisys Corporation and Owens Corning | Paul E. Martin has been a director at STERIS since 2021, with extensive experience in information technology and security. | |
Richard C. Breeden Board | Director | Chairman and CEO of Breeden Capital Management LLC; Chairman of Richard C. Breeden & Co., LLC; Special Master for the U.S. Department of Justice | Richard C. Breeden has been a director at STERIS since 2008 and has extensive experience in financial and regulatory matters. | |
Richard M. Steeves Board | Director | Executive Chairman of Advanced Research Cryptography Ltd.; Chairman of TrustFlight Ltd.; Nonexecutive Chairman of Future Health Works Ltd. | Richard M. Steeves has been a director at STERIS since 2015, with extensive knowledge of healthcare and medical device industries. |
- With the AST segment no longer expected to exit the year at double-digit revenue growth and margins impacted by labor and energy costs, what specific strategies are you implementing to improve AST's growth trajectory and profitability in the face of these challenges?
- Given the anticipated flat to slightly down Healthcare capital equipment revenue for fiscal 2025 due to timing of shipments and difficult fourth quarter comparisons, how confident are you that recurring revenue outperformance can fully offset this decline, and what steps are you taking to drive capital equipment growth?
- The Life Sciences segment is now expected to have flat revenue for the year, with declines in capital equipment sales partially mitigated by consumables. What are the underlying factors contributing to the decline in Life Sciences capital equipment, and how do you plan to address this weakness?
- Labor and energy costs continue to pressure margins, particularly in AST, and you mentioned the inability to immediately pass on increased energy costs to customers. How are you planning to manage these costs, and when do you anticipate seeing margin improvement as a result?
- You reported a one-time loss on a capital equipment order in your med-x business unit that negatively impacted AST margins. Can you provide more details on what led to this loss and what measures you're putting in place to prevent similar issues in the future?
Competitors mentioned in the company's latest 10K filing.
| Company | Description |
|---|---|
Competes on a product basis in the Healthcare segment, which includes infection prevention consumables and capital equipment. | |
Competes on a product basis in the Healthcare segment, which includes infection prevention consumables and capital equipment. | |
Competes on a product basis in the Healthcare segment, which includes infection prevention consumables and capital equipment. | |
Belimed | Competes on a product basis in the Healthcare segment and in the Life Sciences segment, which includes infection prevention consumables and capital equipment. |
Competes on a product basis in the Healthcare segment, which includes infection prevention consumables and capital equipment. | |
Getinge | Competes on a product basis in the Healthcare segment and in the Life Sciences segment, which includes infection prevention consumables and capital equipment. |
Karl Storz | Competes on a product basis in the Healthcare segment, which includes infection prevention consumables and capital equipment. |
Olympus | Competes on a product basis in the Healthcare segment and on a service line basis, which includes infection prevention consumables and capital equipment. |
Ruhof | Competes on a product basis in the Healthcare segment, which includes infection prevention consumables and capital equipment. |
SteelCo | Competes on a product basis in the Healthcare segment, which includes infection prevention consumables and capital equipment. |
Competes on a product basis in the Healthcare segment, which includes infection prevention consumables and capital equipment. | |
Skytron | Competes on a product basis in the Healthcare segment, which includes infection prevention consumables and capital equipment. |
Wassenburg | Competes on a product basis in the Healthcare segment, which includes infection prevention consumables and capital equipment. |
Agiliti | Competes on a service line basis in the Healthcare segment, which includes infection prevention consumables and capital equipment. |
BBraun | Competes on a service line basis in the Healthcare segment, which includes infection prevention consumables and capital equipment. |
Crothall | Competes on a service line basis in the Healthcare segment, which includes infection prevention consumables and capital equipment. |
Pentax | Competes on a service line basis in the Healthcare segment, which includes infection prevention consumables and capital equipment. |
Sterigenics International, Inc. | Competes in the AST segment, which supports medical device and pharmaceutical manufacturers through a global network of contract sterilization and laboratory testing facilities. |
Contec | Competes in the Life Sciences segment, which provides products and services designed to support biopharmaceutical and medical device research and manufacturing facilities. |
Competes in the Life Sciences segment, which provides products and services designed to support biopharmaceutical and medical device research and manufacturing facilities. | |
Fedegari | Competes in the Life Sciences segment, which provides products and services designed to support biopharmaceutical and medical device research and manufacturing facilities. |
Stilmas | Competes in the Life Sciences segment, which provides products and services designed to support biopharmaceutical and medical device research and manufacturing facilities. |
Notable M&A activity and strategic investments in the past 3 years.
| Company | Year | Details |
|---|---|---|
Tuck-in acquisitions in Healthcare and AST segments | 2025 | During the first nine months of fiscal 2025, tuck-in acquisitions with an aggregate consideration of $53.7 million were completed to expand product and service offerings in the Healthcare and AST segments. |
Tuck-in acquisitions in AST and Healthcare segments | 2024 | Fiscal 2024 saw tuck-in acquisitions with an aggregate consideration of $6.5 million, net of cash acquired, aimed at expanding offerings within the AST and Healthcare segments. |
BD Assets Acquisition | 2023 | STERIS acquired BD’s surgical, laparoscopic, and sterilization container assets for $540 million in cash (financed with debt and cash on hand), integrating assets that generated approximately $170 million in annual revenue along with a $60 million tax benefit, bolstering its Healthcare portfolio. |
Tuck-in acquisition in Healthcare segment | 2023 | A Healthcare tuck-in acquisition completed in the first six months of fiscal 2023 involved an aggregate consideration of $21.9 million (including $6.7 million in contingent deferred consideration), intended to enhance the company’s Healthcare offerings despite related integration expenses. |
Cantel Medical LLC Acquisition | 2022 | STERIS acquired Cantel Medical LLC for a total of $3.6 billion (combining cash, STERIS plc shares, and equity components) while assuming and repaying approximately $721 million in debt, which strengthened its infection prevention leadership and expanded its product portfolio. |
Three Smaller Acquisitions in Healthcare | 2022 | These tuck-in acquisitions in fiscal 2022 featured an aggregate consideration of $3.1 million (including $0.1 million in deferred consideration) and were integrated to complement and broaden STERIS’s Healthcare segment offerings. |
No recent press releases or 8-K filings found for STE.